NCT06939777View on ClinicalTrials.gov

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SNA02-48 Injection in Chinese Adult Participants

PHASE1/PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

255

Participants

Timeline

Start Date

April 30, 2025

Primary Completion Date

December 31, 2025

Study Completion Date

February 28, 2026

Conditions

Tetanus

Interventions

BIOLOGICAL

SNA02-48

intramuscular injection

BIOLOGICAL

Placebo

intramuscular injection

BIOLOGICAL

HTIG

intramuscular injection

BIOLOGICAL

Tetanus Toxoid

intramuscular injection

Trial Locations (1)

Unknown

The Second Hospital of Anhui Medical University, Hefei

All Listed Sponsors

lead

Sinovac Life Sciences Co., Ltd.

INDUSTRY

NCT06939777 - Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SNA02-48 Injection in Chinese Adult Participants | Biotech Hunter | Biotech Hunter